Members Wealth LLC Buys Shares of 2,965 Stryker Co. (NYSE:SYK)

Members Wealth LLC bought a new stake in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,965 shares of the medical technology company's stock, valued at approximately $1,143,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. J. W. Coons Advisors LLC increased its position in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after acquiring an additional 26 shares during the period. Mascoma Wealth Management LLC increased its holdings in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares during the period. Opal Wealth Advisors LLC raised its stake in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after purchasing an additional 28 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the period. Finally, JFS Wealth Advisors LLC grew its position in Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after buying an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Up 0.1%

Stryker stock traded up $0.51 during trading hours on Friday, hitting $382.86. The company had a trading volume of 1,993,145 shares, compared to its average volume of 1,342,850. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $146.13 billion, a P/E ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The firm's fifty day moving average is $368.57 and its 200-day moving average is $376.25.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the previous year, the company posted $2.50 EPS. Stryker's revenue was up 11.9% on a year-over-year basis. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker's dividend payout ratio is 45.41%.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SYK. Truist Financial upped their price target on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. BTIG Research set a $403.00 target price on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. Citigroup reiterated a "buy" rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Needham & Company LLC restated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.